Figures computed from official regulatory filings — .
Analysttarget 10 USD (+663%) · consensus 4.25/5 · 3 buy · 1 hold · 0 sell
Ownershipinsiders 5.41% · institutions 21.37% · short 8.6% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for BioAtla, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
21 buys104 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| SHORT JAY M PHDtrack record | Other | $437.7 | SEC |
| Sievers Eric | Other | $226.5 | SEC |
| Vasquez Christiantrack record | Other | $120 | SEC |
| Sievers Eric | Other | $526.6 | SEC |
| SHORT JAY M PHDtrack record | Other | $1K | SEC |
| Vasquez Christiantrack record | Other | $322.3 | SEC |
| Vasquez Christiantrack record | Other | $29.6 | SEC |
| Sievers Eric | Other | $60.8 | SEC |
| SHORT JAY M PHDtrack record | Other | $107.4 | SEC |
| Sievers Eric | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Vasquez Christiantrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SHORT JAY M PHDtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Vasquez Christiantrack record | Other | $450.5 | SEC |
| Sievers Eric | Other | $785 | SEC |
| WALDRON RICHARD A | Other | $682.3 | SEC |
| SHORT JAY M PHDtrack record | Other | $1.9K | SEC |
| SHORT JAY M PHDtrack record | Other | $5.7K | SEC |
| Vasquez Christiantrack record | Other | $1.4K | SEC |
| Sievers Eric | Other | $2.5K | SEC |
| WALDRON RICHARD A | Other | $2.1K | SEC |
| SHORT JAY M PHDtrack record | Other | $2.9K | SEC |
| WALDRON RICHARD A | Other | $1.1K | SEC |
| Sievers Eric | Other | $1.3K | SEC |
| Vasquez Christiantrack record | Other | $720.4 | SEC |
| STEINMAN LAWRENCEtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |